Vis enkel innførsel

dc.contributor.authorBramness, Jørgen Gustav
dc.contributor.authorvon Soest, Tilmann
dc.date.accessioned2019-08-06T09:09:17Z
dc.date.accessioned2019-09-09T12:05:26Z
dc.date.available2019-08-06T09:09:17Z
dc.date.available2019-09-09T12:05:26Z
dc.date.issued2019-02-14
dc.identifier.citationBramness JG, von Soest TvS. A longitudinal study of cannabis use increasing the use of asthma medication in young Norwegian adults 11 Medical and Health Sciences 1117 Public Health and Health Services 11 Medical and Health Sciences 1102 Cardiorespiratory Medicine and Haematology. BMC Pulmonary Medicine. 2019;19(1)en
dc.identifier.issn1471-2466
dc.identifier.issn1471-2466
dc.identifier.urihttps://hdl.handle.net/10642/7507
dc.description.abstractBackground: A small number of studies have shown that the use of cannabis increases the risk of bronchial asthma. There is, however, a paucity of longitudinal studies which are able to control for known risk factors of bronchial asthma. Methods: Survey data from a population-based longitudinal study encompassing 2602 young adults followed for 13years were coupled with individual prescription data on asthma medication (β2-adrenergic receptor agonists and glucocorticoids for inhalation) from the Norwegian national prescription database, which covers the entire Norwegian population. Current cannabis use, gender, age, years of education, body mass index (BMI; kg/m2) and current smoking were measured. Results: Prescription of asthma medication was associated with female gender, self-reported earlier asthma and allergies, daily tobacco smoking and current cannabis use. In a model adjusting for gender, age, years of education, BMI, earlier self-reported asthma and allergies and current tobacco smoking the odds ratio for a current cannabis user to fill prescriptions for asthma medication was 1.71 (95% CI: 1.06–2.77; p=0.028). Conclusions: This suggests that cannabis is a risk factor for bronchial asthma or use of asthma medication even when known risk factors are taken into consideration. Intake of cannabis through smoking should be avoided in persons at risk.en
dc.description.sponsorshipThe data collection was funded by several grants from the Research Council of Norway.en
dc.language.isoenen
dc.publisherBMC (part of Springer Nature)en
dc.relation.ispartofseriesBMC Pulmonary Medicine; (2019) 19:52
dc.rightsThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectAdolescentsen
dc.subjectCannabisen
dc.subjectAsthma medicationen
dc.subjectLongitudinal studiesen
dc.subjectSmokingen
dc.titleA longitudinal study of cannabis use increasing the use of asthma medication in young Norwegian adults 11 Medical and Health Sciences 1117 Public Health and Health Services 11 Medical and Health Sciences 1102 Cardiorespiratory Medicine and Haematologyen
dc.typeJournal articleen
dc.typePeer revieweden
dc.date.updated2019-08-06T09:09:17Z
dc.description.versionpublishedVersionen
dc.identifier.doihttps://dx.doi.org/10.1186/s12890-019-0814-x
dc.identifier.cristin1703878
dc.source.journalBMC Pulmonary Medicine


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Med mindre annet er angitt, så er denne innførselen lisensiert som This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.